Pacitora Biotech

Pacitora is a biotechnology company dedicated to developing first-in-class small molecule therapies for life-threatening inflammatory conditions and critical care medicine. Founded by world-leading scientists from the University of Oxford, the company focuses on modulating the nitric oxide pathway by targeting the enzyme DDAH1. Their lead program aims to treat sepsis and acute respiratory distress syndrome (ARDS) by restoring vascular tone and preventing organ failure. By inhibiting DDAH1, Pacitora's approach seeks to address the underlying pathophysiology of cytokine storms and systemic inflammation. The company is backed by prominent life science investors and leverages deep expertise in immunology and vascular biology.